Table 2.

Association between first-line brand vs. generic bisphosphonates and adherence to treatment during the first year after bisphosphonates initiation (N = 3,329).

	Brand bisphosphonate N = 1,834	Generic bisphosphonate N = 1,495	Relative Risk [CI 95%]
Time to discontinuation (d), median [Q1; Q3]	103 [63;365]	119 [61;365]	1.08 [1.02; 1.14]a,b
Class of CMA7, n (%)c
<90%	173/728 (23.8)	139/635 (21.9)	0.90 [0.85; 0.95]a,d
≥90%	555/728 (76.2)	496/635 (78.1)

^aModels excluded 15 patients due to missing prescriber specialty.

^bHazard-Ratio [CI 95%] for discontinuationestimated from weighted Fine and Gray’s model accounting for competing risk of death with IPTW weights assigned to each patient (reference = “generic bisphosphonate” group).

^cThis analysis included the 1,364 patients under bisphosphonate treatment during at least 6 months (728 patients in the “brand bisphosphonate” group and 635 in the “generic bisphosphonate” group).

^dRisk ratio [CI 95%] for a good implementation estimated using weighted log–binomial regression model with IPTW weights assigned to each patient (reference = “generic bisphosphonate” group).